Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs

Current treatments with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection lead to elimination of the virus in more than 95% of patients, regardless of the HCV genotype or presence of advanced liver fibrosis [1]. The AASLD and EASL guidelines both recommend combinations including an NS5A inhibitor with either a NS3/4 protease inhibitor such as grazoprevir/elbasvir or glecaprevir/pibrentasvir, or a nucleotide analogue plus an NS5A inhibitor such as sofosbuvir/velpatasvir for durations ranging from 8 to 12 weeks [2 –4].

Source: Journal of Hepatology - June 12, 2019 Category: Gastroenterology Authors: Jordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, Mois és Diago, Alba Cachero, Javier García-Samaniego, Isabel Conde, Ana Arencibia, Juan Arenas, Francisco Gea, Xavier Torras, José Luis Calleja, José Antonio Carrión, Inmaculada Fernández, Rosa Marà Source Type: research